# Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement

> **NCT00683267** · PHASE2 · TERMINATED · sponsor: **Anesiva, Inc.** · enrollment: 118 (actual)

## Conditions studied

- Arthroplasty

## Interventions

- **DRUG:** 4975, highly purified capsaicin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00683267
- **Lead sponsor:** Anesiva, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2008-11
- **Final completion:** 2008-12
- **Target enrollment:** 118 (ACTUAL)
- **Why stopped:** Enrollment of patients has halted prematurely and will not resume. No future patients will be enrolled or treated.
- **Last updated:** 2009-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683267, "Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00683267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*